News

Immune NK T-cells may be therapeutic target for IPF

Certain immune cells called natural killer (NK) T-cells are present at higher numbers in the lungs of people with idiopathic pulmonary fibrosis (IPF) than in the lungs of healthy people, according to data announced by GRI Bio. Also, the more NK T-cells, the greater the number of macrophages,…

First patient enrolled in TETON PPF study of nebulized Tyvaso

The first patient has been enrolled in a Phase 3 clinical trial of nebulized Tyvaso (treprostinil) inhalation solution for treating progressive pulmonary fibrosis (PPF), according to United Therapeutics, the therapy’s developer. Called TETON PPF (NCT05943535), the study will evaluate how safe Tyvaso is versus a placebo…

BMS-986278 declared breakthrough therapy for progressive PF

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF). Breakthrough therapy designation is intended to expedite the development and review of medicines for serious or life-threatening diseases. The decision is based on preliminary…

Rituximab, chemotherapy elevate PF risk after COVID-19: Study

Use of cancer chemotherapy agents or rituximab to treat autoimmune diseases was associated with an increased risk of pulmonary fibrosis (PF) in people hospitalized with COVID-19, according to a large-scale U.S. study. Exposure to these medications, along with anti-inflammatory corticosteroids and amiodarone, used to treat certain heart rhythm disorders,…

Study finds how extracellular histones drive lung fibrosis

Proteins called histones can trigger lung fibrosis (scarring) by prompting platelets, cell fragments involved in blood clotting, to release a signaling molecule called transforming growth factor beta 1 (TGFB1), a new study found. TGFB1, in turn, blocks the production of interleukin-27 (IL-27), a signaling molecule that normally helps to limit…

Inhaled AP01 likely more effective, safer than Esbriet, Ofev

Treatment with AP01, Avalyn Pharma‘s experimental inhaled formulation of pirfenidone, appears to be slightly more effective for idiopathic pulmonary fibrosis (IPF) than the oral version, which is sold as Esbriet, and results in fewer side effects. AP01’s efficacy and safety profiles with progressive forms of pulmonary…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums